Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA

MT Newswires Live03-18

Telix Pharmaceuticals (TLX) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.

The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.

Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.

Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520244096?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-18 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520244096","market":"fut","top_or_hot":-1,"title":"Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA","media":"MT Newswires Live","content":"<html><body><p> Telix Pharmaceuticals (TLX) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.</p><p>The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.</p><p>Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.</p><p>Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-18 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Telix Pharmaceuticals (TLX) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.</p><p>The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.</p><p>Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.</p><p>Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520244096","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520244096","pubTimestamp":1742298364,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK4139":"生物科技","BK7067":"生物科技","TLX":"Telix Pharmaceuticals Ltd. (Uplisting)","JYNT":"The Joint Corp."},"translate_title":"Telix Pharmaceuticals的Illuccix在巴西获批用于前列腺癌成像；与R2PHARMA成立合资企业","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JYNT":1,"TLX":1,"TLX.AU":1},"content_text":"Telix Pharmaceuticals (TLX) said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520244096"}